---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002826"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:12:32.042252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025

## Summary
- Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.
- Quarter-end cash $5.8M; closed $5.8M PIPE at 25% premium with new investor.
- Phase 2 trial of agenT-797 in gastroesophageal cancers actively enrolling; initial results expected H2 2024.
- MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models (AACR data).
- Upcoming ATS presentation (May 21) on agenT-797 in severe respiratory distress in a renal transplant patient.

## SEC filing metadata
- accession: 0001171843-24-002826
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/f8k_051424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002826
- JSON: https://secwatch.observer/filing/0001171843-24-002826.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002826.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.
  - Period: for the first quarter 2024
  - Net income: $3.8 million, or $0.11 per share
  - EPS: $0.11 per share
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.